This inventor holds 60 USPTO granted patents and 21 published patent applications and 6 EPO patents, primarily in Genome Editing (CPC class C12N). Top assignees: Samsung Electronics Co., Ltd., Electronics and Telecommunications Research Institute, Hyundai Electronics Industries Co. Ltd.. Active years: 1998-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Suwon, KR (1998)
- Ulsan, KR (2001)
- Taejon, KR (2001)
- Daegu, KR (2001)
- Daejeon-shi, KR (2003 - 2004)
- Kyoungki-do, KR (2002 - 2005)
- Taejon-shi, KR (2002 - 2006)
- Kyunggi-do, KR (2006)
- Taejeon-shi, KR (2004 - 2008)
- Jeonju-si, KR (2014)
- Namyangju-si, KR (2014 - 2017)
- Daejeon, KR (2001 - 2019)
- Hwaseong-si, KR (2020 - 2021)
- Seoul, KR (2006 - 2022)
Company Filing History:
13 out of 132,108 
9 out of 11,790 
8 out of 2,340 
Years Active: 1998-2026
Areas of Expertise:
Title: Innovations and Contributions of Jin Soo Kim in Genetic Research
Introduction
Jin Soo Kim is a prominent inventor based in Seoul, South Korea, known for his significant contributions to genetic research and biotechnology. With an impressive portfolio of 57 patents, Kim has made a remarkable impact in the field, particularly in developing methods that enhance the precision of genetic modifications.
Latest Patents
Among his latest patents, one notable innovation is the "Method for detecting off-target sites of programmable nucleases in a genome." This invention introduces a sophisticated method for identifying off-target sites generated by programmable nucleases through extensive data analysis and whole genome sequencing. The Digenome-seq technology presented in this patent allows researchers to detect off-target effects with high reproducibility, ultimately facilitating the creation of programmable nucleases with enhanced target specificity.
Another significant patent is the "RNA guided endonuclease targeting blood coagulation factor VIII intron 1 inversion gene and composition for treating hemophilia comprising same." This invention outlines a method to induce and correct inversions in the blood coagulation factor VIII gene, which is predominantly associated with severe hemophilia A. By employing induced pluripotent stem cells, this innovative approach holds the promise of restoring normal genetic function and advancing therapeutic strategies for hemophilia treatment.
Career Highlights
Jin Soo Kim has held key positions in esteemed organizations, including Samsung Electronics Co., Ltd. and the Electronics and Telecommunications Research Institute. His work in these companies has facilitated the advancement of genetic research technologies and their applications in medicine.
Collaborations
Throughout his career, Kim has collaborated with notable colleagues such as Jae Chang Jung and Ki Ho Baik. These collaborations have enabled the exchange of ideas and fostered innovations that contribute to breakthroughs in genetic research.
Conclusion
Jin Soo Kim's extensive contributions to genetics and biotechnology underscore the importance of innovation in addressing complex medical issues like hemophilia. With his impressive array of patents and collaborations, he continues to be a driving force in the advancement of genetic research, paving the way for future innovations that could transform healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile